BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29753010)

  • 21. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing.
    Ye L; Zhou X; Huang F; Wang W; Qi Y; Xu H; Yang S; Shen L; Fei X; Xie J; Cao M; Zhou Y; Zhu W; Wang S; Ning G; Wang W
    Nat Commun; 2017 Jun; 8():15533. PubMed ID: 28580939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma.
    Chen X; Lin S; Lin Y; Wu S; Zhuo M; Zhang A; Zheng J; You Z
    J Transl Med; 2022 Feb; 20(1):79. PubMed ID: 35123502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.
    Fakhruddin N; Jabbour M; Novy M; Tamim H; Bahmad H; Farhat F; Zaatari G; Aridi T; Kriegshauser G; Oberkanins C; Mahfouz R
    Sci Rep; 2017 Jul; 7(1):4666. PubMed ID: 28680105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
    Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
    BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
    Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
    Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Characterization of Differentiated Thyroid Carcinoma.
    Song YS; Park YJ
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):1-10. PubMed ID: 30912334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Papillary thyroid carcinoma tall cell variant shares accumulation of mitochondria, mitochondrial DNA mutations, and loss of oxidative phosphorylation complex I integrity with oncocytic tumors.
    Tsybrovskyy O; De Luise M; de Biase D; Caporali L; Fiorini C; Gasparre G; Carelli V; Hackl D; Imamovic L; Haim S; Sobrinho-Simões M; Tallini G
    J Pathol Clin Res; 2022 Mar; 8(2):155-168. PubMed ID: 34792302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth.
    Johnson DN; Furtado LV; Long BC; Zhen CJ; Wurst M; Mujacic I; Kadri S; Segal JP; Antic T; Cipriani NA
    Arch Pathol Lab Med; 2018 Jul; 142(7):838-850. PubMed ID: 29582677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma.
    Lu Z; Zhang Y; Feng D; Sheng J; Yang W; Liu B
    Oncotarget; 2017 Jul; 8(28):45784-45792. PubMed ID: 28507274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
    Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
    World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution and Impact of Subclonal Mutations in Papillary Thyroid Cancer.
    Masoodi T; Siraj AK; Siraj S; Azam S; Qadri Z; Parvathareddy SK; Al-Sobhi SS; AlDawish M; Alkuraya FS; Al-Kuraya KS
    Am J Hum Genet; 2019 Nov; 105(5):959-973. PubMed ID: 31668701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles.
    Lu Z; Sheng J; Zhang Y; Deng J; Li Y; Lu A; Zhang J; Yu H; Zhang M; Xiong Z; Yan H; Diplas BH; Lu Y; Liu B
    J Pathol; 2016 May; 239(1):72-83. PubMed ID: 27071483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
    Stanojevic B; Dzodic R; Saenko V; Milovanovic Z; Pupic G; Zivkovic O; Markovic I; Djurisic I; Buta M; Dimitrijevic B; Rogounovitch T; Mitsutake N; Mine M; Shibata Y; Nakashima M; Yamashita S
    Endocr J; 2011; 58(5):381-93. PubMed ID: 21498916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
    Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF mutation in papillary thyroid cancer-Prevalence and clinical correlation in a South-East Asian cohort.
    Goh X; Lum J; Yang SP; Chionh SB; Koay E; Chiu L; Parameswaran R; Ngiam KY; Loh TKS; Nga ME; Lim CM
    Clin Otolaryngol; 2019 Mar; 44(2):114-123. PubMed ID: 30294871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.